Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient
Joint Authors
Frassetto, Lynda Ann
Gibson, Suzanne
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-04-21
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Uric acid accumulates in renal failure and is thought to be a uremic toxin—that is, higher levels of uric acid are more damaging to the kidneys.
Urate crystals can precipitate in the kidney tubules, cause urate stones, and promote inflammatory changes in the renal interstitium and vascular endothelium.
Uric acid is also a small non-protein-bound molecule and therefore easily dialyzable.
Here, we present the case of an anuric hemodialysis patient with severe tophaceous gout who regained some renal function and whose gout burden significantly decreased resulting in marked improvement in functional status using a new gout medication, febuxostat, and increased frequency of dialysis.
American Psychological Association (APA)
Frassetto, Lynda Ann& Gibson, Suzanne. 2016. Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient. Case Reports in Nephrology،Vol. 2016, no. 2016, pp.1-3.
https://search.emarefa.net/detail/BIM-1101233
Modern Language Association (MLA)
Frassetto, Lynda Ann& Gibson, Suzanne. Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient. Case Reports in Nephrology No. 2016 (2016), pp.1-3.
https://search.emarefa.net/detail/BIM-1101233
American Medical Association (AMA)
Frassetto, Lynda Ann& Gibson, Suzanne. Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient. Case Reports in Nephrology. 2016. Vol. 2016, no. 2016, pp.1-3.
https://search.emarefa.net/detail/BIM-1101233
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1101233